The PDX-1 tumor growth rate was significantly lowered by KYA1797K treatment (p < 0.01) (Fig. 5e), and the reduction in β-catenin, pan-RAS, and EGFR expression levels in tumor tissues was confirmed (Fig. 5f–h). The gene discussed is EGFR; the disease is neoplasm.